ICM20 for Advanced Cancer

"This clinical trial is targeting candidates aged 18 to 70. For those younger than the age of consent, there are 3 studies available and 24 for elderly patients over 65 years old."

"The safety of Dose Level 2 is estimated to be a 1, as it has only been tested in preliminary trials and there is limited evidence on its efficacy."

"Affirmative. Clinicaltrials.gov reports that this experiment, which was first advertised on December 20th 2022, is currently recruiting participants. A total of 24 individuals need to be recruited from one single medical facility before the trial can commence."

"That is correct. As per the clinicaltrials.gov records, this clinical trial is presently soliciting patients. The initial post was made on December 20th 2022 and most recently revised then same day - 24 participants are needed to be recruited from a single site."

"This clinical trial is seeking 24 individuals aged 18-70 who are contending with safety issues. In addition to this criteria, accepted participants must have a hemoglobin level of at least 9 g/dl, over 1000 polymorphonuclear white blood cells, more than 50,000 platelets & liver function tests below double the upper limit of normal; serum creatinine levels should be no higher than 2.0 and prothrombin time & partial thromboplastin time must remain within their respective norms. The human immunodeficiency virus status needs to be negative while those recruited need to weigh between 125 - 200 pounds and"

"According to the IC-MedTech Corporation, who is sponsoring this trial, the main outcome to be measured over a 90 day period will involve monitoring Treatment-Emergent Adverse Events. Additionally, further secondary outcomes such as clinical changes from baseline (including physical examination review of systems), vital signs fluctuations and treatment tolerance at Day 48/60 are also being assessed."